Education
About Us
Working with TipRanks
Follow Us
Eagle Pharmaceuticals Inc (EGRX)
OTHER OTC:EGRX
| Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 316.61M | $ 171.55M | $ 187.80M | $ 195.89M | $ 213.31M |
| Gross Profit | $ 221.67M | $ 129.37M | $ 142.34M | $ 135.00M | $ 151.40M |
| Operating Income | $ 80.96M | $ 2.77M | $ 32.95M | $ 21.82M | $ 36.62M |
| EBITDA | $ 77.50M | $ 847.00K | $ 30.02M | $ 29.34M | $ 40.44M |
| Net Income | $ 35.64M | $ -8.63M | $ 11.99M | $ 14.31M | $ 31.90M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 55.32M | $ 97.66M | $ 103.16M | $ 109.78M | $ 78.79M |
| Total Assets | $ 406.16M | $ 253.73M | $ 253.19M | $ 254.55M | $ 238.60M |
| Total Debt | $ 67.79M | $ 29.82M | $ 38.22M | $ 38.56M | $ 44.41M |
| Net Debt | $ 12.47M | $ -72.05M | $ -66.06M | $ -71.22M | $ -34.39M |
| Total Liabilities | $ 172.60M | $ 77.28M | $ 67.18M | $ 75.38M | $ 77.84M |
| Stockholders' Equity | $ 233.56M | $ 176.45M | $ 186.01M | $ 179.17M | $ 160.76M |
| Cash Flow | |||||
| Free Cash Flow | $ 50.52M | $ 27.90M | $ 48.75M | $ 55.21M | $ 52.25M |
| Operating Cash Flow | $ 50.70M | $ 28.22M | $ 49.50M | $ 55.99M | $ 52.38M |
| Investing Cash Flow | $ -86.83M | $ -5.32M | $ -18.25M | $ -777.00K | $ -133.00K |
| Financing Cash Flow | $ -6.21M | $ -28.39M | $ -37.87M | $ -24.23M | $ -88.12M |
Eagle Pharmaceuticals Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.